Apixaban
- Generic Name
- Apixaban
- Brand Names
- Eliquis, Apixaban Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C25H25N5O4
- CAS Number
- 503612-47-3
- Unique Ingredient Identifier
- 3Z9Y7UWC1J
- Background
Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases. It is marketed under the name Eliquis. Apixaban was approved by the FDA on December 28, 2012.
- Indication
Apixaban is indicated for reducing the risk of stroke and systemic embolism in patients who have nonvalvular atrial fibrillation, prophylaxis of deep vein thrombosis(DVT) leading to pulmonary embolism(PE) in patients after a hip or knee replacement surgery, and treatment of DVT and PE to reduce the risk of recurrence.
- Associated Conditions
- Deep Vein Thrombosis, Deep vein thrombosis recurrent, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Stroke, Systemic Embolism
- Associated Therapies
- -
HElping Alleviate the Longer-term Consequences of COVID-19 (HEAL-COVID)
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2021-07-23
- Target Recruit Count
- 2631
- Registration Number
- NCT04801940
- Locations
- 🇬🇧
Addenbrookes Hospital, Cambridge, United Kingdom
Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 19002
- Registration Number
- NCT04736719
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Effect of Prophylactic and Therapeutic Anticoagulants in Egyptian Patients With COVID-19
- Conditions
- Interventions
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 90
- Registration Number
- NCT04736901
- Locations
- 🇪🇬
Teachers Hospital, Cairo, Please Select, Egypt
Effects of APIXaban on BRAIN Protection in Patients With Sinus Rhythm and Heart Failure: APIXBRAIN-HF Trial
- Conditions
- Interventions
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2021-01-20
- Lead Sponsor
- Korea University Guro Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT04696120
- Locations
- 🇰🇷
Chungnam National University Hospital, Daejeon, Korea, Republic of
🇰🇷Severance Hospital, Seoul, Korea, Republic of
🇰🇷Korea University Guro Hospital, Seoul, Guro-gu, Korea, Republic of
Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With Medicare
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 107383
- Registration Number
- NCT04681482
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
NOACs in Oral and Maxillofacial Surgery: Impact on Post-operative Complications
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- Malmö University
- Target Recruit Count
- 216
- Registration Number
- NCT04662515
- Locations
- 🇸🇪
Skåne University Hospital, Helsingborg, Sweden
🇸🇪Department of Oral and Maxillofacial Surgery and Oral Medicine, Faculty of Odontology, Malmö University, Malmö, Sweden
Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT）
- First Posted Date
- 2020-11-27
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Northern Jiangsu People's Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT04645550
- Locations
- 🇨🇳
Clinical Medical College of Yangzhou University, Yangzhou, Jiangsu, China
COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation
- First Posted Date
- 2020-11-24
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 3018
- Registration Number
- NCT04642430
- Locations
- 🇨🇦
University Ottawa Heart Institute, Ottawa, Ontario, Canada
🇨🇦CISSS de l'Outaouais, Gatineau, Quebec, Canada
🇨🇦Ciusss Nim, Montreal, Quebec, Canada
Anticoagulation in Patients With Venous Thromboembolism and Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-11-06
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT04618913
- Locations
- 🇬🇧
Pfizer Investigational Site, London, United Kingdom
Replication of the ARISTOTLE Anticoagulant Trial in Healthcare Claims Data
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 220518
- Registration Number
- NCT04593030
- Locations
- 🇺🇸
Brigham And Women's Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.